melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling
Melior Discovery
home
Therapeutic Areas
Safety Assessment
 
 

theraTRACE

Melior Pharmaceuticals

              

 

             

 

                 

melior melior melior discovery melior pharmaceuticals preclinical services pre-clinical services in vivo pharmacology in vivo efficacy efficacy models pharmacokinetics indications discovery specialized animal models bioanalytical services theratrace exton pennsylvania cro contract research drug discovery drug development metabolic disease alzheimer’s alzheimers diabetes reprofiling

Melior Discovery pain/neuropathic

Formalin Analgesia Assay
The formalin chemical nociception assay is a commonly used analgesia assay that is typically included in a battery of analgesic tests. Formalin produces a painful irritation when injected into the skin of experimental animals that can be measured as a licking response.  Formalin nociception is typically described as occurring in two phases: Phase I which is an acute response to the formalin injection and occurs almost immediately after injection and lasting for between 5 to 10 minutes, and Phase II, which lasts from approximately 20 to 40 minutes after inejction is caused by a central sensitzation activity. 

Formalin induced chemical nociception can be attenuated by classical anti-nociceptive agents including opiods and GABA enhancers. We include the formalin assay in a battery of analgesia assays that include the thermal nociceptive assay and the touch sensitivity assay. 

                       formalin analgesia assay

The formalin pain assay measures a compound's analgesic effect.  Vehicle treated mice peaked within the first five minutes (early phase) of monitoring with a nearly continuous display of pain behavior.  Following this peak, there was a classic "no response" period that lasted for approximately 10 minutes.  Vehicle treated mice then entered the late phase response period where pain behaviors were again more pronouced.  Administration of Oxycodone significantly reduced the pain response in both the early and late phases.  Data are mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001 compared to vehicle. 

 

If you are interested in learning more about the Formalin Analgesia Assay, please contact models@meliordiscovery.com to start the conversation today.